Brief: Kuros Biosciences Treatment Of First Patient In Its Spinal Fusion Trial With Fibrin-PTH

Kuros Biosciences AG

01/09/2020 06:06

Sept 1 (Reuters) - KUROS BIOSCIENCES AG  KURN.S :
    * ANNOUNCES TREATMENT OF FIRST PATIENT IN ITS SPINAL FUSION
TRIAL
WITH FIBRIN-PTH
    * PRIMARY ENDPOINT IS RADIOGRAPHIC INTERBODY FUSION AT 12
MONTHS
    * POTENTIAL TO ADDRESS A MAJOR COMMERCIAL OPPORTUNITY

Source text for Eikon:  ID:nTENtq5f0a 
Further company coverage:  KURN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))